For research use only. Not for therapeutic Use.
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC50 of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. [1].
BNC375 significantly potentiates the acetylcholine signal without changing the rapid receptor desensitization[1].
BNC375 (0.003-10.0 mg/kg, administered orally) exhibits the MED of 0.03 mg/kg, and achieves full reversal of the Scopolamine-induced impairment at 1.0 mg/kg in mouse T-maze model. BNC375 exhibits the plasm half-life (t1/2) of 1.2 h[1].
| Catalog Number | I018993 |
| CAS Number | 1557240-80-8 |
| Synonyms | 4-[(1R,3R)-3-[(5-chloro-2-methoxyanilino)methyl]-2,2-dimethylcyclopropyl]benzenesulfonamide |
| Molecular Formula | C19H23ClN2O3S |
| Purity | ≥95% |
| InChI | InChI=1S/C19H23ClN2O3S/c1-19(2)15(11-22-16-10-13(20)6-9-17(16)25-3)18(19)12-4-7-14(8-5-12)26(21,23)24/h4-10,15,18,22H,11H2,1-3H3,(H2,21,23,24)/t15-,18-/m1/s1 |
| InChIKey | LWWDCTBUJUEFDE-CRAIPNDOSA-N |
| SMILES | CC1(C(C1C2=CC=C(C=C2)S(=O)(=O)N)CNC3=C(C=CC(=C3)Cl)OC)C |
| Reference | [1]. Andrew J Harvey, et al. Discovery of BNC375, a Potent, Selective, and Orally Available Type I Positive Allosteric Modulator of α7 nAChRs. ACS Med Chem Lett. 2019 Mar 25;10(5):754-760. |
